Nanosphere Inc (NASDAQ:NSPH)

CAPS Rating: 1 out of 5

Results 1 - 20 of 28 : 1 2 Next »

Recs

0
Member Avatar joaquingrech (98.25) Submitted: 11/24/2015 5:19:30 AM : Underperform Start Price: $1.25 NSPH Score: +36.86

scam

Recs

2
Member Avatar SmartAce (99.90) Submitted: 9/16/2015 12:09:22 PM : Underperform Start Price: $2.32 NSPH Score: +70.10

Jed maybe we are the same person and don't even realize it. It has been a while since I read any Philip K. Dick novels, but it sounds like a definite possibility.

Recs

3
Member Avatar jed71 (99.85) Submitted: 9/16/2015 11:06:49 AM : Underperform Start Price: $2.26 NSPH Score: +69.32

Let's just suffice it to say that Smartace and I are very obviously perusing some of the same websites. There seem to be some recent paid stock promotions going on here. I read the recent 10-Q and there is almost nothing I like about this firm. The financial picture is horrible and I don't see how they are serving their shareholders' interests.

I looked back 5 years, and don't see any profit over that period of time. Their free cash flow is very negative, they have HUGE SG&A / R&D expenses (unsupportable over the long term), and their balance sheet is a wreck. Like with most of these issues, my guess is they reverse split soon, and issue more shares. If that option dries up, you all know what will happen next.

Recs

0
Member Avatar Hendrickson71 (< 20) Submitted: 9/14/2015 11:16:56 AM : Outperform Start Price: $2.14 NSPH Score: -68.85

Chardan Capital Begins Coverage on Nanosphere, “Buy” rating, $3.30 price target. Analysts predict that Nanosphere will post ($5.19) EPS for the current year.

Recs

0
Member Avatar Aquest (63.97) Submitted: 9/8/2015 4:08:28 PM : Outperform Start Price: $2.84 NSPH Score: -76.05

Interesting diagnostic method that has many more potential tests to be approved. Each approved test increases sales.

Recs

0
Member Avatar Ooker (53.50) Submitted: 4/23/2015 2:29:59 PM : Underperform Start Price: $4.05 NSPH Score: +78.28

Nobody wanted this stock at 25 cents. Why would they want it at 4 dollars?

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 10/28/2013 6:26:16 AM : Outperform Start Price: $42.80 NSPH Score: -115.48

IHS pattern

Recs

2
Member Avatar rknapton (63.79) Submitted: 8/22/2013 4:35:38 PM : Underperform Start Price: $42.20 NSPH Score: +123.69

Short. Company is bleeding tons of cash and keeps issuing stock to make up for it. This thing is toast.

Recs

0
Member Avatar lshreve1 (< 20) Submitted: 5/24/2013 4:37:49 PM : Outperform Start Price: $85.20 NSPH Score: -122.61

NSPH is very small, but they are doing the RIGHT THING with their products, and the recent increase in share price suggests that others think that they are doing THINGS RIGHT with the business. Their approved products are directed at saving the lives of very sick people. Sepsis is usually 80% fatal, but if the attending physician immediately identifies a pathogen behind sepsis along with expected resistance to specific antibiotics, treatment with best potential outcome can commence quickly. The companies products perform direct nucleic acid identification thereby directly fingering specific DNA (bacteria) now and soon probably RNA (virus) as well as conditions related to genetic contents.

Recs

0
Member Avatar 350zchaser (< 20) Submitted: 4/6/2013 9:24:48 PM : Outperform Start Price: $47.00 NSPH Score: -131.23

Nsph has no debt and a solid audience. I firmly believe they will outperform the market

Recs

0
Member Avatar tmac1227 (< 20) Submitted: 3/20/2013 11:08:20 AM : Outperform Start Price: $47.60 NSPH Score: -131.02

The diagnostics market is huge. Nanosphere offers quick turn diagnostics tools for providers, in the 1-2 hour range v. days with current technology. This is important since decisions can be made on the correct course of action for antibiotics. Since the resistance to antibiotics is a growing concern these diagnostic tools are becoming critical to providers as they wish to target the right antibiotic as fast as they can.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 2/17/2013 9:44:32 PM : Outperform Start Price: $37.20 NSPH Score: -133.32

Last weeks drop in share price was an over reaction to the management changes. The sudden replacement of the CEO without any clearly articulated reasons spooked the market. With an FDA approved lab instrument and 4 currently approved tests for that instrument. The company uses the "razor and blades" revenue model. The company should be cash flow positive within 12 to 18 months and presently has sufficient cash to make that goal.

Recs

0
Member Avatar birdup (26.11) Submitted: 3/10/2012 11:20:40 AM : Outperform Start Price: $39.20 NSPH Score: -147.18

Verigene system

Recs

0
Member Avatar Boum (< 20) Submitted: 5/6/2010 4:38:20 PM : Outperform Start Price: $104.40 NSPH Score: -181.94

Just a min after the kind BravoBevo it's good, but I prefer to be first like for ACUR...
However the most difficut is to know the right time for selling...

Recs

0
Member Avatar iddqkfyou (< 20) Submitted: 4/20/2010 2:43:36 PM : Outperform Start Price: $119.30 NSPH Score: -170.09

Rapid diagnostics are going to be the next big thing.

Recs

0
Member Avatar facerbird (< 20) Submitted: 4/19/2010 2:02:12 AM : Outperform Start Price: $100.20 NSPH Score: -172.59

It's good,I like it

Recs

0
Member Avatar grahamfordummies (59.48) Submitted: 3/19/2010 12:13:15 AM : Outperform Start Price: $90.20 NSPH Score: -175.55

Well positioned in an industry that is poised for a dramatic acceleration in growth as predictive medicine and molecular diagnostics begin to gain traction. Recent weakness primarily driven by shorter term concerns present a great entry point for longer term investors. While still burning cash (although moderatimg), a solid cash position (over $2 per share in net cash) provides sufficient financial flexibility. A good insider rating (recent CEO and 30% owner buys with no sells) is also encouraging.

Recs

0
Member Avatar fastop (< 20) Submitted: 9/9/2008 3:35:34 PM : Outperform Start Price: $172.40 NSPH Score: -171.46

Love the technology. Risks = they are thinly traded and very volatile.

Recs

0
Member Avatar lovemunny (< 20) Submitted: 6/10/2008 2:10:49 AM : Outperform Start Price: $166.20 NSPH Score: -154.68

This company is doing really cool things and think it would change our lives if it became the market leader in the emerging field of genetic and nano testing.

Recs

0
Member Avatar jatava (31.69) Submitted: 5/21/2008 10:33:12 PM : Outperform Start Price: $177.80 NSPH Score: -153.11

25,000

Results 1 - 20 of 28 : 1 2 Next »

Featured Broker Partners